Taysha Gene Therapies, Inc.
TSHA
$6.85
$0.030.44%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 9.56% | 6.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 28.71% | -0.70% | |||
| Operating Income | -53.66% | 16.82% | |||
| Income Before Tax | -52.27% | 14.91% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -52.27% | 14.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -52.27% | 14.91% | |||
| EBIT | -53.66% | 16.82% | |||
| EBITDA | -54.25% | 17.00% | |||
| EPS Basic | -48.52% | 15.87% | |||
| Normalized Basic EPS | -84.17% | 34.54% | |||
| EPS Diluted | -48.52% | 15.87% | |||
| Normalized Diluted EPS | -84.17% | 34.54% | |||
| Average Basic Shares Outstanding | 2.61% | 1.14% | |||
| Average Diluted Shares Outstanding | 2.61% | 1.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||